European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular L...
TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lym...
3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More
AbbVie is a Dividend King that's poised for future growth. Enbridge offers an ultra-high dividend yield and is expanding into more areas of the energy sector.
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.
3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income
AbbVie enables retirees to profit from both its dividend payouts and its promising growth opportunities. Verizon has a safe high-yielding dividend, which the company has been growing steadily in re...
Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon
Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income ...
3 Stocks Retirees Should Absolutely Love
AbbVie offers reliable income and solid growth prospects. Bristol Myers Squibb is a stable dividend stock to buy and hold.
2 High Yielding Recession Proof Dividend Picks For A Massive Income Snowball
10,000 boomers are reaching retirement age every day. The 4% rule for retirement withdrawals may not always work due to sequence risk and market fluctuations. Building a dividend income snowball ca...
3 Passive Income Dividend Stocks To Buy Now
Seasoned investors tend to closely follow the ups and downs of the market.
High-Yield Harvest: 3 Of My Favorite Dividend Stocks For What's Next
The tech rally is losing steam as economic indicators, including rising unemployment and weak manufacturing data, suggest increasing recession risks. Investors are shifting focus from high-growth t...
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.
AbbVie: Q2 Earnings Validate Bullish Case
AbbVie's recent Q2 earnings release was robust, validating my initial bullish thesis, which has aged well as the stock has outperformed the broader market since mid-April. The Q2 earnings release s...
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative ...
The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The approval is supported by data from two pivotal Phase 3 trials: The INSPIRE ind...
AbbVie Stock Hits Record High on Demand for Non-Humira Portfolio
AbbVie (ABBV) shares traded at an all-time high Thursday as the biopharmaceutical firm posted better-than-expected revenue and boosted its guidance as demand for its other drugs offset a decline in...
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.91 per share a year ago.
AbbVie Stock Is Rising on Strong Earnings. CEO Cites ‘Significant Momentum.
AbbVie reported second-quarter adjusted earnings of $2.65 a share on revenue of $14.46 billion.
Related Companies